What is he best known for?
The fields of study he is best known for:
- Immune system
- Gene
- Cancer
Immunology, Cell biology, T cell, Antigen and Immune system are his primary areas of study.
His Cell biology study combines topics from a wide range of disciplines, such as Receptor, IL-2 receptor and CD80.
Koji Tamada has included themes like Cytokine, Immune tolerance, Cancer immunotherapy, Molecular biology and Cytotoxic T cell in his T cell study.
Within one scientific family, Koji Tamada focuses on topics pertaining to Tumor necrosis factor alpha under Cancer immunotherapy, and may sometimes address concerns connected to Cancer research.
His work in Antigen covers topics such as B7-H1 Antigen which are related to areas like Blockade.
His Immune system research is multidisciplinary, incorporating elements of Interleukin 12 and Infiltration.
His most cited work include:
- Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion (3453 citations)
- B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion (1957 citations)
- Blockade of B7-H1 and PD-1 by Monoclonal Antibodies Potentiates Cancer Therapeutic Immunity (829 citations)
What are the main themes of his work throughout his whole career to date?
His main research concerns Immunology, Cancer research, Immune system, T cell and Cytotoxic T cell.
Koji Tamada focuses mostly in the field of Immunology, narrowing it down to matters related to Interleukin 12 and, in some cases, CD40.
His Cancer research course of study focuses on Tumor necrosis factor alpha and Signal transduction.
His studies in T cell integrate themes in fields like Molecular biology, CD80, Immune tolerance and Cell biology.
Transplantation is closely connected to T lymphocyte in his research, which is encompassed under the umbrella topic of Cytotoxic T cell.
His Antigen research integrates issues from Tumor microenvironment, B7-H1 Antigen and Clonal anergy.
He most often published in these fields:
- Immunology (55.21%)
- Cancer research (36.98%)
- Immune system (30.21%)
What were the highlights of his more recent work (between 2018-2021)?
- Cancer research (36.98%)
- Antigen (20.83%)
- Antibody (10.42%)
In recent papers he was focusing on the following fields of study:
Koji Tamada mostly deals with Cancer research, Antigen, Antibody, Immune system and Cancer immunotherapy.
His research in Cancer research intersects with topics in Chemokine, Chimeric antigen receptor, Immunotherapy and Cell therapy.
He specializes in Antigen, namely Peptide vaccine.
T cell and CD8 are the core of his Immune system study.
His T cell research includes elements of Cytotoxic T cell and Dendritic cell.
Koji Tamada has researched Cancer immunotherapy in several fields, including Vector, Blockade, Clinical trial and Virology.
Between 2018 and 2021, his most popular works were:
- Inhibitory functions of PD-L1 and PD-L2 in the regulation of anti-tumor immunity in murine tumor microenvironment (19 citations)
- Non-clinical efficacy, safety and stable clinical cell processing of induced pluripotent stem cell-derived anti-glypican-3 chimeric antigen receptor-expressing natural killer/innate lymphoid cells. (13 citations)
- Improved survival of chimeric antigen receptor-engineered T (CAR-T) and tumor-specific T cells caused by anti-programmed cell death protein 1 single-chain variable fragment-producing CAR-T cells. (12 citations)
In his most recent research, the most cited papers focused on:
- Gene
- Immune system
- Cancer
The scientist’s investigation covers issues in Cancer research, Chimeric antigen receptor, Immunotherapy, Antigen and Tumor microenvironment.
His studies deal with areas such as Immunohistochemistry, Peptide vaccine, Human leukocyte antigen, XCL1 and Programmed cell death as well as Cancer research.
His Human leukocyte antigen study integrates concerns from other disciplines, such as Glypican 3, Immune system, Poly ICLC, Antibody and TIGIT.
He is involved in the study of Immune system that focuses on T cell in particular.
His biological study spans a wide range of topics, including Induced pluripotent stem cell, Innate lymphoid cell, Interferon gamma and Cancer immunotherapy.
His Tumor microenvironment study combines topics in areas such as Haematopoiesis, Ligand, Downregulation and upregulation, Immunity and PD-L1.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
